doi: 10.1038/nri.2016.70 35 CretenetGClercIMatiasMLoiselSCraveiroMOburogluLet al
The appropriate dosage and frequency may vary depending on an individuals health history, symptoms, nutritional needs, and wellness goals
Even the most promising peptide protocol will produce suboptimal results if the biological foundation is not in place
Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion
A growing body of scientific evidence on mammalian systems indicates that AITC treatment arrests the cell cycle, causes apoptosis and inhibits the proliferation of cancer cells leading to reduced tumour formation in certain types of cancer 14,15
Here's how they compare: Peptide Primary research area FDA status Advisory committee review BPC-157 Tissue repair, angiogenesis Not approved Yes (free base + acetate) TB-500 Actin regulation, cell migration Not approved Yes MOTS-c Mitochondrial metabolism Not approved Yes KPV Anti-inflammatory Not approved Yes GHK-Cu Copper-peptide skin/healing Not approved Not on 2026 agenda For a deeper comparison of BPC-157 and its most-researched counterpart, see our BPC-157 vs TB-500 research comparison